← Oncology Approval Tracker

FDA DECISION ·

Carvykti

ciltacabtagene autoleucel · Janssen Biotech / Legend Biotech

FDA approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after at least four previous lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

LAMPGEN ANALYSIS

Why it matters

The initial BCMA CAR T-cell approval was for a heavily pretreated population.

What research teams should watch

Reconstruct prior lines and agent classes before planning leukapheresis and bridging therapy.

PRIMARY RECORDS

Sources